Shanghai Bio-heart Biological Technology Co (HKSE:02185) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Shanghai Bio-heart Biological Technology Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Shanghai Bio-heart Biological Technology Co's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.00.

Shanghai Bio-heart Biological Technology Co's long-term debt to total assets ratio declined from Jun. 2023 (0.01) to Jun. 2024 (0.00). It may suggest that Shanghai Bio-heart Biological Technology Co is progressively becoming less dependent on debt to grow their business.

Shanghai Bio-heart Biological Technology Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Shanghai Bio-heart Biological Technology Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Bio-heart Biological Technology Co LT-Debt-to-Total-Asset Chart

Shanghai Bio-heart Biological Technology Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

0.01

Shanghai Bio-heart Biological Technology Co Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial					0.01	0.01	0.01	-	-

Shanghai Bio-heart Biological Technology Co LT-Debt-to-Total-Asset Calculation

Shanghai Bio-heart Biological Technology Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.2	/	894.601
	=

Shanghai Bio-heart Biological Technology Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	0.172	/	843.811
	=

Shanghai Bio-heart Biological Technology Co (HKSE:02185) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Shanghai Bio-heart Biological Technology Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Shanghai Bio-heart Biological Technology Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Bio-heart Biological Technology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Bio-heart Biological Technology Co Ltd (HKSE:02185) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.590 Ruiqing Road, Room 302, 3rd Floor, Building 4 & Building 6, East Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN

Website

http://www.bio-heart.com

Shanghai Bio-heart Biological Technology Co Ltd is engaged in the research and development of bioresorbable scaffold (BRS) products and the renal denervation (RDN) system. The company is a interventional cardiovascular device company in China, and locate in Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. Focused on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension.

Executives

Tpg Operating Group Ii, L.p.	2201 Interest of corporation controlled by you
Chen Hao	2201 Interest of corporation controlled by you
Zhu Linan	2201 Interest of corporation controlled by you
Wang Nengguang	2201 Interest of corporation controlled by you
Union Season Holdings Limited	2201 Interest of corporation controlled by you
Sk China Company Limited	2201 Interest of corporation controlled by you
Right Lane Limited	2201 Interest of corporation controlled by you
Proud Solar Limited	2201 Interest of corporation controlled by you
Magic Grace Limited	2101 Beneficial owner
Loft Success Investments Limited	2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii, L.p.	2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii Gp Limited	2201 Interest of corporation controlled by you
Lc Fund Gp Limited	2201 Interest of corporation controlled by you
Great Unity Fund I, L.p.	2201 Interest of corporation controlled by you
Lian Xiang Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you

Shanghai Bio-heart Biological Technology Co Headlines

No Headlines